JP2022058280A - Composition for inhibiting plaque formation - Google Patents

Abstract

To inhibit plaque formation or maturation on a tooth surface.SOLUTION: A composition for inhibiting plaque formation contains a quaternary ammonium salt having a C10-C14 alkyl group and preferably further contains cetylpyridinium chloride.SELECTED DRAWING: None

Description

The present disclosure relates to a composition for suppressing plaque (dental plaque) formation and the like. The contents of all documents described in this specification are incorporated herein by reference.

Plaque (plaque) is a biofilm in which oral microorganisms are aggregated and is thought to be a cause of dental caries and periodontal disease. For this reason, plaque control, especially suppression of plaque formation, is important.

Roughly speaking, plaques are formed as follows. That is, first, a thin film of saliva called "pellicle" or a protein derived from physiological gingival crevicular fluid is formed on the tooth surface, and facultative anaerobic bacteria (initial adherent bacteria) such as streptococcus are transmitted to the tooth surface through the pellicle. Adhere to. Mediator bacteria such as Fusobacterium that co-aggregate with various oral bacteria adhere to this initial adherent bacterium, and later adherent bacteria such as anaerobic bacteria Porphyromonas gingivalis and Treponema denticola adhere via the mediator bacterium. -Agglutination and plaque mature. In particular, it is known that late-stage adherent bacteria cause periodontal disease and are directly or indirectly related to the destruction of periodontal tissue.

J Dent Res 90 (11): 1271-1278, 2011

From the above, it is important to suppress the formation of plaque on the tooth surface, especially to suppress the adhesion and aggregation of late-stage adherent bacteria and the maturation of plaque in order to prevent periodontal disease.

The present inventors focused on Fusobacterium, which is a mediator, and conducted a study. If the action of Fusobacterium, which is a mediator that can co-aggregate with various bacteria, can be suppressed, it is possible to suppress the adhesion and aggregation of late-adherent bacteria to the tooth surface, which in turn suppresses the maturation of plaque formation. This is because it is considered possible.

Therefore, we proceeded with the study of a method for sterilizing Fusobacterium. However, even when various fungicides usually used in oral compositions were examined, it was not possible to find a fungicide capable of efficiently killing Fusobacterium.

Cetylpyridinium chloride, which is an example of a bactericidal agent usually used in oral compositions, is no exception, and no efficient bactericidal effect on Fusobacterium was observed. However, the present inventors further studied and found that cetylpyridinium chloride is C16 alkylpyridinium chloride, and the length of this alkyl group may affect the bactericidal effect on fuzobacterium, and further improvements were made. rice field.

The present disclosure includes, for example, the subjects described in the following sections.
Item 1.
A composition for suppressing plaque formation containing a quaternary ammonium salt having a C10 to C14 alkyl group.
Item 2.
A composition for suppressing plaque formation containing a quaternary ammonium salt having a C10 to C14 alkyl group and cetylpyridinium chloride.
Item 3.
The quaternary ammonium salt having a C10 to C14 alkyl group is
Equation (1):

（式中、ＲはＣ１０～Ｃ１４直鎖アルキル基を示し、ＸはＣｌ又はＢｒを示す）で表される化合物、並びに
式（２）：

(In the formula, R represents a C10 to C14 linear alkyl group, X represents Cl or Br), and the formula (2) :.

（式中、Ｒ^１はＣ１０～Ｃ１４直鎖アルキル基を示し、Ｒ^２及びＲ^３は同一又は異なってＣ１～Ｃ４アルキル基を示し、ＸはＣｌ又はＢｒを示す）で表される化合物
からなる群より選択される少なくとも１種である、
項１又は２に記載の組成物。
項４．
Ｃ１０～Ｃ１４アルキル基を有する第四級アンモニウム塩が、
式（１ａ）：

(In the formula, R ¹ represents a C10 to C14 linear alkyl group, R ² and R ³ represent the same or different C1 to C4 alkyl groups, and X represents Cl or Br). At least one selected from the group,
Item 2. The composition according to Item 1 or 2.
Item 4.
The quaternary ammonium salt having a C10 to C14 alkyl group is
Equation (1a):

（式中、Ｒは前記に同じ）で表される化合物、並びに
式（２ａ）：

Compounds represented by (in the formula, R is the same as above), and formula (2a) :.

（式中、Ｒ^１は前記に同じ）で表される化合物
からなる群より選択される少なくとも１種である、
項３に記載の組成物。
項５．
塩化セチルピリジニウムからなる、Ｃ１０～Ｃ１４アルキル基を有する第四級アンモニウム塩のプラーク形成抑制効果増強剤。
項６．
Ｃ１０～Ｃ１４アルキル基を有する第四級アンモニウム塩が、
式（１）：

(In the formula, R ¹ is at least one selected from the group consisting of the compounds represented by the above).
Item 3. The composition according to Item 3.
Item 5.
An agent for enhancing the plaque formation inhibitory effect of a quaternary ammonium salt having a C10 to C14 alkyl group, which is composed of cetylpyridinium chloride.
Item 6.
The quaternary ammonium salt having a C10 to C14 alkyl group is
Equation (1):

（式中、ＲはＣ１０～Ｃ１４直鎖アルキル基を示し、ＸはＣｌ又はＢｒを示す）で表される化合物、並びに
式（２）：

(In the formula, R represents a C10 to C14 linear alkyl group, X represents Cl or Br), and the formula (2) :.

（式中、Ｒ^１はＣ１０～Ｃ１４直鎖アルキル基を示し、Ｒ^２及びＲ^３は同一又は異なってＣ１～Ｃ４アルキル基を示し、ＸはＣｌ又はＢｒを示す）で表される化合物
からなる群より選択される少なくとも１種である、
項５に記載のプラーク形成抑制効果増強剤。
項７．
Ｃ１０～Ｃ１４アルキル基を有する第四級アンモニウム塩が、
式（１ａ）：

(In the formula, R ¹ represents a C10 to C14 linear alkyl group, R ² and R ³ represent the same or different C1 to C4 alkyl groups, and X represents Cl or Br). At least one selected from the group,
Item 5. The plaque formation inhibitory effect enhancer according to Item 5.
Item 7.
The quaternary ammonium salt having a C10 to C14 alkyl group is
Equation (1a):

（式中、Ｒは前記に同じ）で表される化合物、並びに
式（２ａ）：

Compounds represented by (in the formula, R is the same as above), and formula (2a) :.

（式中、Ｒ^１は前記に同じ）で表される化合物
からなる群より選択される少なくとも１種である、
項６に記載のプラーク形成抑制効果増強剤。
項８．
塩化セチルピリジニウムからなる、Ｃ１０～Ｃ１４アルキル基を有する第四級アンモニウム塩のフゾバクテリウム殺菌効果増強剤。
項９．
Ｃ１０～Ｃ１４アルキル基を有する第四級アンモニウム塩が、
式（１）：

(In the formula, R ¹ is at least one selected from the group consisting of the compounds represented by the above).
Item 6. The plaque formation inhibitory effect enhancer.
Item 8.
An agent for enhancing the bactericidal effect of a quaternary ammonium salt having a C10 to C14 alkyl group, which comprises cetylpyridinium chloride.
Item 9.
The quaternary ammonium salt having a C10 to C14 alkyl group is
Equation (1):

（式中、ＲはＣ１０～Ｃ１４直鎖アルキル基を示し、ＸはＣｌ又はＢｒを示す）で表される化合物、並びに
式（２）：

(In the formula, R represents a C10 to C14 linear alkyl group, X represents Cl or Br), and the formula (2) :.

（式中、Ｒ^１はＣ１０～Ｃ１４直鎖アルキル基を示し、Ｒ^２及びＲ^３は同一又は異なってＣ１～Ｃ４アルキル基を示し、ＸはＣｌ又はＢｒを示す）で表される化合物
からなる群より選択される少なくとも１種である、
項８に記載のフゾバクテリウム殺菌効果増強剤。
項１０．
Ｃ１０～Ｃ１４アルキル基を有する第四級アンモニウム塩が、
式（１ａ）：

(In the formula, R ¹ represents a C10 to C14 linear alkyl group, R ² and R ³ represent the same or different C1 to C4 alkyl groups, and X represents Cl or Br). At least one selected from the group,
Item 8. The Fusobacterium bactericidal effect enhancer according to Item 8.
Item 10.
The quaternary ammonium salt having a C10 to C14 alkyl group is
Equation (1a):

（式中、Ｒは前記に同じ）で表される化合物、並びに
式（２ａ）：

Compounds represented by (in the formula, R is the same as above), and formula (2a) :.

（式中、Ｒ^１は前記に同じ）で表される化合物
からなる群より選択される少なくとも１種である、
項９に記載のフゾバクテリウム殺菌効果増強剤。

(In the formula, R ¹ is at least one selected from the group consisting of the compounds represented by the above).
Item 9. The Fusobacterium bactericidal effect enhancer according to Item 9.

Efficient methods are provided for killing Fusobacterium, a mediator of plaque formation. This also makes it possible to efficiently suppress plaque formation.

The results of examining the fusobacterium bactericidal effect of a quaternary ammonium salt (CPC and / or DPC) having a C10 to C14 alkyl group are shown. The results of examining the fusobacterium bactericidal effect of a quaternary ammonium salt (CPC and / or OPC) having a C10 to C14 alkyl group are shown. The results of examining the fusobacterium bactericidal effect of a quaternary ammonium salt having a C10 to C14 alkyl group (CPC and / or BKC12, BKC14, or BKC16) are shown. The results of the Fusobacterium bactericidal effect study of alkylpyridinium chloride (CPC and DPC) are shown. The results of the Fusobacterium bactericidal effect study of alkylpyridinium chloride (CPC and OPC) are shown. The results of the Fusobacterium bactericidal effect study of the composition containing CPC and / or DPC are shown. The results of the Fusobacterium bactericidal effect study of the composition containing CPC and / or DPC are shown. The results of the Fusobacterium bactericidal effect study of alkylpyridinium chloride (CPC and DPC) are shown. The results of the Fusobacterium bactericidal effect study of alkylpyridinium chloride (CPC and DPC) are shown.

Hereinafter, each embodiment included in the present disclosure will be described in more detail. The present disclosure preferably includes, but is not limited to, a plaque formation inhibitory composition, a plaque formation inhibitory effect enhancer, and the like, and the present disclosure includes all disclosed in the present specification and recognized by those skilled in the art. do.

The compositions included in the present disclosure contain a quaternary ammonium salt having a C10-C14 (C10, C11, C12, C13, or C14) alkyl group, preferably further containing cetylpyridinium chloride. The composition may be referred to as "the composition of the present disclosure". The composition of the present disclosure is suitable for suppressing plaque formation, and the case of being used for this purpose may be particularly referred to as "the composition for suppressing plaque formation of the present disclosure".

As the quaternary ammonium salt having a C10 to C14 alkyl group, a chloride salt or a bromide salt is preferable. Further, the alkyl group may be in the form of a straight chain or a branched chain, and is preferably a straight chain.

More specifically, as the quaternary ammonium salt having a C10 to C14 alkyl group, for example, the formula (1):

（式中、ＲはＣ１０～Ｃ１４直鎖アルキル基を示し、ＸはＣｌ又はＢｒを示す）で表される化合物、並びに式（２）：

(In the formula, R represents a C10 to C14 linear alkyl group, X represents Cl or Br), and the formula (2) :.

（式中、Ｒ^１はＣ１０～Ｃ１４直鎖アルキル基を示し、Ｒ^２及びＲ^３は同一又は異なってＣ１～Ｃ４アルキル基を示し、ＸはＣｌ又はＢｒを示す）で表される化合物が、好ましく挙げられる。なお、ここでのＣ１～Ｃ４アルキル基は直鎖又は分岐鎖状であってよく、好ましくは直鎖である。特に限定はされないが、メチル基又はエチル基が好ましく、Ｒ^２及びＲ^３がともにメチル基であることが特に好ましい。また、「Ｃ数字」は炭素原子数を表す。また、当該式（１）で表される化合物を「化合物（１）」、当該式（２）で表される化合物を「化合物（２）」ということがある。

(In the formula, R ¹ represents a C10 to C14 linear alkyl group, R ² and R ³ represent the same or different C1 to C4 alkyl groups, and X represents Cl or Br). Preferred. The C1 to C4 alkyl groups here may be in the form of a straight chain or a branched chain, and are preferably straight chains. Although not particularly limited, a methyl group or an ethyl group is preferable, and it is particularly preferable that both R ² and R ³ are methyl groups. The "C number" represents the number of carbon atoms. Further, the compound represented by the formula (1) may be referred to as "compound (1)", and the compound represented by the formula (2) may be referred to as "compound (2)".

Among the compounds (1), the formula (1a):

（式中、Ｒは前記に同じ）で表される化合物がより好ましい。

The compound represented by (in the formula, R is the same as described above) is more preferable.

Further, among the compounds (2), the formula (2a):

（式中、Ｒ^１は前記に同じ）で表される化合物がより好ましい。

The compound represented by (in the formula, R ¹ is the same as described above) is more preferable.

The quaternary ammonium salt having a C10 to C14 alkyl group can be used alone or in combination of two or more.

The compositions of the present disclosure are excellent by containing a quaternary ammonium salt having a C10-C14 (C10, C11, C12, C13, or C14) alkyl group, preferably further containing cetylpyridinium chloride. It can show the bactericidal effect of fuzobacterium. This makes it possible to exert an excellent effect of suppressing plaque formation.

Therefore, the composition of the present disclosure can also be preferably used as a composition for sterilizing Fusobacterium.

The Fusobacterium here is not particularly limited as long as it is a bacterium belonging to the genus Fusobacterium, which is a mediator between the early and late adherent bacteria in plaque formation, but Fusobacterium nucleatum is preferably exemplified.

When the composition of the present disclosure contains cetylpyridinium chloride, the content ratio of the quaternary ammonium salt having a C10 to C14 alkyl group to cetylpyridinium chloride is, for example, 10 parts by mass of the quaternary ammonium salt. On the other hand, about 1 to 100 parts by mass of cetylpyridinium chloride is preferable. The upper or lower limit of the range (1 to 100 parts by mass) is, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, It may be 94, 95, 96, 97, 98, or 99 parts by mass. For example, the range may be about 2 to 90 parts by mass or about 5 to 50 parts by mass.

The content of the quaternary ammonium salt having a C10 to C14 alkyl group in the composition of the present disclosure is not particularly limited as long as the effect is exhibited, but is, for example, 0.005 to 0.5% by mass. The degree is mentioned. The upper or lower limit of the range is, for example, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1. , 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0 .23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 32, 0.33, 0.34, 0.35, 0 .36, 0.37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48 , 0.49% by mass. For example, the range may be about 0.01 to 0.3% by mass.

When the composition of the present disclosure contains cetylpyridinium chloride, the content of cetylpyridinium chloride is not particularly limited as long as the effect is exhibited, but is, for example, 0.01 to 0.5 mass. % Is mentioned. The upper or lower limit of the range is, for example, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11. , 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0 .24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 32, 0.33, 0.34, 0.35, 0.36, 0 .37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49 It may be% by mass. For example, the range may be about 0.02 to 0.3% by mass or about 0.03 to 0.1% by mass.

As described above, the present inventors have found that cetylpyridinium chloride alone does not have an efficient bactericidal effect on fuzobacterium, but as a result of further studies, cetylpyridinium chloride has a C10 to C14 alkyl group. It was found that the quaternary ammonium salt has the effect of enhancing the bactericidal effect of fuzobacterium. Therefore, when the composition of the present disclosure contains cetylpyridinium chloride, it can exhibit a particularly excellent Fusobacterium bactericidal effect and, by extension, an effect of suppressing plaque formation.

Therefore, the present disclosure discloses a plaque formation of a quaternary ammonium salt having a C10 to C14 alkyl group consisting of cetylpyridinium chloride and a quaternary ammonium salt having a C10 to C14 alkyl group consisting of cetylpyridinium chloride. It also includes an inhibitory effect enhancer. The above description of cetylpyridinium chloride and the quaternary ammonium salt having a C10-C14 alkyl group for the compositions of the present disclosure is preferably applicable to the enhancer as it is.

The composition of the present disclosure can be particularly preferably used as an oral composition. Further, since the oral composition is useful for sterilizing Fusobacterium, it can also be preferably used for sterilizing Fusobacterium. That is, the composition of the present disclosure can be preferably used as an oral composition for suppressing plaque formation or for sterilizing Fusobacterium. When the composition of the present disclosure is used as an oral composition, the composition may be referred to as "the oral composition of the present disclosure".

The oral composition of the present disclosure may be a solid composition or a liquid composition. The oral composition can be used, for example, as a pharmaceutical product or a quasi-drug. The form of the oral composition of the present disclosure is not particularly limited, but according to a conventional method, for example, an ointment, a paste, a pasta, a gel, a liquid, a spray, a mouthwash, a liquid dentifrice, and the like. It can be in the form (dosage form) of dentifrice, gum, etc. Of these, mouthwash, liquid dentifrice, dentifrice, ointment, paste, liquid, and gel are preferable.

The oral composition of the present disclosure may contain any component that can be blended in the oral composition alone or in combination of two or more, as long as the effect is not impaired.

For example, as the surfactant, a nonionic surfactant, an anionic surfactant or an amphoteric surfactant can be blended. Specifically, for example, sugar fatty acid esters such as sucrose fatty acid ester, maltose fatty acid ester, and lactose fatty acid ester; fatty acid alkanolamides; sorbitan fatty acid ester; fatty acid monoglyceride; polyoxyethylene addition coefficient is 8 as a nonionic surfactant. Polyoxyethylene alkyl ether having a polyoxyethylene addition coefficient of 10 to 10 and an alkyl group having 13 to 15 carbon atoms; a polyoxyethylene alkylphenyl ether having an alkyl group having 9 carbon atoms; diethyl sebacate; Polyoxyethylene cured castor oil; fatty acid polyoxyethylene sorbitan and the like can be mentioned. Examples of the anionic surfactant include sulfate ester salts such as sodium lauryl sulfate and sodium polyoxyethylene lauryl ether sulfate; sulfosuccinates such as sodium lauryl sulfosuccinate and sodium polyoxyethylene lauryl ether sulfosuccinate; sodium cocoyl sarcosine and lauroyl methyl alanine. Acrylic amino acid salts such as sodium; cocoyl methyl taurine sodium and the like can be mentioned. Examples of the amphoteric ion surfactant include betaine acetate-type active agents such as lauryldimethylaminoacetic acid betaine and betaine coconut oil fatty acid amide propyldimethylaminoacetic acid betaine; and imidazoline-type active agents such as N-cocoyl-N-carboxymethyl-N-hydroxyethylethylenediamine sodium. Activator; Examples thereof include amino acid type activators such as N-lauryldiaminoethylglycine. These surfactants can be blended alone or in combination of two or more. The blending amount is usually 0.1 to 5% by mass with respect to the total amount of the composition.

Further, as a flavoring agent, for example, menthol, carboxylic acid, anator, eugenol, methyl salicylate, limonene, osimene, n-decyl alcohol, citronell, α-terpineol, methyl acetate, citronenyl acetate, methyl eugenol, cineole, etc. Lina roll, ethyl lina roll, timol, spare mint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, siliceous oil, perilla oil, winter green oil, clove oil, eucalyptus oil, pimento oil, d-campul, Fragrances such as d-borneol, uikyo oil, keihi oil, cinnamaldehyde, peppermint oil, vanillin and the like can be used. These can be blended, for example, in an amount of 0.001 to 1.5% by mass based on the total amount of the composition, either alone or in combination of two or more.

Further, as the sweetening agent, for example, sodium saccharin, acesulfarm potassium, stebioside, neohesperidyldihydrochalcone, perillartine, taumatin, aspalathylphenylalanylmethyl ester, p-methoxycinnamic aldehyde and the like can be used. These can be blended, for example, 0.01 to 1% by mass with respect to the total amount of the composition.

Further, as a wetting agent, sorbitol, ethylene glycol, propylene glycol, glycerin, 1,3-butylene glycol, polypropylene glycol, xylit, martit, lacchit, polyoxyethylene glycol and the like may be blended alone or in combination of two or more. can.

As the preservative, parabens such as methylparaben, ethylparaben, propylparaben and butylparaben, sodium benzoate, phenoxyethanol, alkyldiaminoethylglycine hydrochloride and the like can be blended.

As the colorant, legal pigments such as Blue No. 1, Yellow No. 4, Red No. 202, and Green No. 3, mineral pigments such as ultramarine, enhanced ultramarine, and dark blue, titanium oxide, and the like may be blended.

As the pH adjuster, citric acid, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphate, acetic acid, nitric acid, chemically possible salts thereof, sodium hydroxide and the like may be blended. These can be blended alone or in combination of two or more so that the pH of the composition is in the range of 4 to 8, preferably 5 to 7. The blending amount of the pH adjuster may be, for example, 0.01 to 2% by weight.

The oral composition of the present disclosure includes not only a quaternary ammonium salt having a C10 to C14 alkyl group and cetylpyridinium chloride, but also dl-α-tocopherol acetate, tocopherol succinate, or tocopherol nicotinate as a medicinal ingredient. Vitamin E such as vitamin E, amphoteric bactericides such as dodecyldiaminoethylglycine, nonionic bactericides such as triclosan, isopropylmethylphenol and hinokithiol, anionic bactericides such as sodium lauroyl sarcosin, cations such as chlorhexidine hydrochloride and benzethonium chloride. Bactericides, dextranases, amylases, proteases, mutanases, lysoteams, enzymes such as lytic enzyme (lytecenzyme), alkali metal monofluorofluoride such as sodium monofluorophosphate and potassium monofluorophosphate, sodium fluoride, fluoride. Fluoride such as stannous acid, tranexamic acid, epsilon aminocaproic acid, aluminum chlorhydroxyl allantoin, dihydrocholesterol, glycyrrhetinic acid, glycyrrhizinic acid, sodium copper chlorophyllin, glycerophosphate, chlorophyll, sodium chloride, caropeptide, allantin, carbazochrome, hinokithiol , Potassium nitrate, palatinit and the like can be blended alone or in combination of two or more.

Further, as a base, alcohols, silicon, apatite, white petrolatum, paraffin, liquid paraffin, microcrystalline wax, squalane, plastic base and the like can be added.

In addition, the oral composition of the present disclosure can be prepared by a known method or a method easily conceived from a known method. For example, it can be prepared by appropriately mixing a quaternary ammonium salt having a C10 to C14 alkyl group, preferably cetylpyridinium chloride, and if necessary, other components and the like.

The subject to which the oral composition of the present disclosure is applied is not particularly limited, and human and non-human mammals are preferably mentioned. As the non-human mammal, livestock and pets are preferable, and more specifically, for example, dogs, cats, mice, rats, horses, cows, sheep, monkeys and the like can be mentioned. Further, as described above, the oral composition of the present disclosure contains a quaternary ammonium salt having a C10 to C14 alkyl group, preferably cetylpyridinium chloride, so that Fusobacterium, which is a mediator, can be efficiently sterilized. It can be said that it is particularly suitable for application to the oral cavity of a subject in which plaque is not formed or is in the process of formation (no late-adhering bacteria are attached).

The above-mentioned description of the oral composition of the present disclosure may be applied as it is to the composition of the present disclosure which is not used as the oral composition (for example, it may be used for cleaning dentures).

As used herein, the term "contains" also includes "consisting essentially" and "consisting" (The term "comprising" includes "consisting essentially of" and "consisting of."). In addition, the present disclosure includes all combinations of the constituent elements described herein.

In addition, the various characteristics (property, structure, function, etc.) described for each embodiment of the present disclosure described above may be combined in any way in specifying the subject matter included in the present disclosure. That is, the present disclosure includes all subjects consisting of any combination of each of the combinable properties described herein.

Hereinafter, embodiments of the present disclosure will be described in more detail with reference to examples, but the embodiments of the present disclosure are not limited to the following examples.

Examination of bactericidal effect of quaternary ammonium salt on fuzobacterium Each component contains the following alkylpyridinium chloride and benzylalkyldimethylammonium chloride at their respective concentrations (0.01%, 0.02%, 0.03%, 0.04%). , 0.05%, 0.07%, or 0.10%) and used as a bactericidal solution. In the disinfectant solution, each of the above components was used alone or in combination. The alkylpyridinium chloride concentration (%) of the disinfectant solution is w / v%, but since the solvent is water and the concentration is relatively low, it is almost a numerical value of mass% (w / w%). Can be approximated as it is.

Octylpyridinium chloride (OPC): R = (CH ₂ ) ₇ CH ₃ in the following equation
Dodecylpyridinium chloride (DPC): R = (CH ₂ ) ₁₁ CH ₃ in the following equation
Cetylpyridinium chloride (CPC): R = (CH ₂ ) ₁₅ CH ₃ by the following formula

Benzyl chloride decyldimethylammonium (BKC12):
In the following formula, R ¹ = C ₁₂ H ₂₅
Benzyl chloride tetradecyldimethylammonium (BKC14):
In the following formula, R ¹ = C ₁₄ H ₂₉
Benzyl chloride hexadecyldimethylammonium (BKC16):
In the following formula, R ¹ = C ₁₆ H ₃₃

In addition, the following two subspecies of Fusobacterium were used as test bacteria.
Bacteria 1: Fusobacterium nucleatum subsp. Nucleatum ATCC23726
Fungus 2: Fusobacterium nucleatum subsp. Nucleatum ATCC25586

The test bacteria were inoculated into 10 ml of GAM bouillon medium (Nissui Pharmaceutical Co., Ltd.) and anaerobically cultured at 37 ° C. for 2 days. The culture solution was used as a test bacterial solution.

200 μl of the test bacterial solution was mixed with 200 μl of the fungicide solution having different concentrations. Thirty seconds after mixing, 100 μl of the mixed solution was collected, and soy lecithin and Tween 80 were added to phosphate buffered saline (PBS) to a final concentration of 0.07% and 0.5%, respectively, to inactivate the drug. 900 μl of PBS was added (the mixture was diluted 10-fold) to inactivate the bactericidal action of the bactericidal agent. In addition, the mixed solution was serially diluted with drug-inactivated PBS, and the mixed solution was diluted ¹⁰ to ¹⁰⁷ times (stepwise mixed solution diluted solution).

A 100 μl diluted solution of the prepared step mixture was smeared on a sheep blood agar medium for CDC anaerobic bacteria (Nippon Becton Dickinson Co., Ltd.), and the cells were anaerobically cultured at 37 ° C. for 3 days, and the viable cell count was counted.

The results are shown in FIGS. 1, 2, and 3. In addition, these figures are graphs with Log (live cell count) CFU / ml as the vertical axis, but the value is 2 as the detection limit. (If the value is less than 2, it means that the product has been sterilized to less than 100 CFU.) In addition, the concentrations of CPC, DPC, OPC, BKC12, BKC14, and BKC16 in these figures and the following figures are prepared as a disinfectant solution. The concentration of the said component is shown.

It was found that CPC and OPC have no bactericidal effect on Fusobacterium, while DPC has a bactericidal effect on Fusobacterium even at relatively low concentrations. It was also found that CPC alone does not show a bactericidal effect on Fusobacterium, but when combined with DPC, it enhances the bactericidal effect of DPC on Fusobacterium.
Here, the results when OPC, DPC, or CPC are used alone are picked up from FIGS. 1 and 2 and shown in FIGS. 4a and 4b.

Similarly, it was found that BKC16 does not show a bactericidal effect on Fusobacterium, while BKC14 or BKC12 shows a bactericidal effect on Fusobacterium even at a relatively low concentration. It was also found that CPC alone does not show a bactericidal effect on Fusobacterium, but when combined with BKC14 or BKC12, it enhances the Fusobacterium bactericidal effect of BKC14 or BKC12.

Examination of the bactericidal effect of the composition containing the quaternary ammonium salt and CPC on fuzobacterium A liquid composition containing each concentration of the quaternary ammonium salt and CPC was added to these components and added to water and a solvent (glycerin). It was prepared by mixing a fragrance, a preservative, a solubilizer (polyoxyethylene hydrogenated castor oil) and the like.

Using the liquid composition, the bactericidal effect was examined in the same manner as above. The results are shown in FIG.

In addition, the bactericidal effect of the liquid composition on more Fusobacterium subspecies was examined in the same manner as described above. That is, the bactericidal effect was examined using the following bacteria 3, fungus 4, fungus 5, fungus 6, and fungus 7 instead of fungi 1 and 2. The results are shown in FIG.
Fungus 3: Fusobacterium necrophorum subsp. Necrophorum ATCC25286
Fungus 4: Fusobacterium nucleatum subsp. Polymorphum ATCC10953
Fungus 5: Fusobacterium nucleatum subsp. Fusiforme ATCC51190
Bacteria 6: Fusobacterium nucleatum subsp. Vincentii ATCC49256
Fungus 7: Fusobacterium nucleatum subsp. Animalis ATCC51191

It was confirmed that the DPC and CPC-containing compositions examined sterilized Fusobacterium to below the detection limit.
Furthermore, in the same manner as described above, the bactericidal effect of the composition containing each concentration of alkylpyridinium chloride alone or in combination against Fusobacterium was reexamined. The results are shown in FIGS. 7a and 7b.

An example of prescription is shown below. In the following formulation examples, the value of each component indicates mass%.

Prescription example [Liquid gel]

[Toothpaste]

Claims (10)

A composition for suppressing plaque formation containing a quaternary ammonium salt having a C10 to C14 alkyl group. A composition for suppressing plaque formation containing a quaternary ammonium salt having a C10 to C14 alkyl group and cetylpyridinium chloride. The quaternary ammonium salt having a C10 to C14 alkyl group is
Equation (1):

(In the formula, R represents a C10 to C14 linear alkyl group, X represents Cl or Br), and the formula (2) :.

(In the formula, R ¹ represents a C10 to C14 linear alkyl group, R ² and R ³ represent the same or different C1 to C4 alkyl groups, and X represents Cl or Br). At least one selected from the group,
The composition according to claim 1 or 2. The quaternary ammonium salt having a C10 to C14 alkyl group is
Equation (1a):

Compounds represented by (in the formula, R is the same as above), and formula (2a) :.

(In the formula, R ¹ is at least one selected from the group consisting of the compounds represented by the above).
The composition according to claim 3. An agent for enhancing the plaque formation inhibitory effect of a quaternary ammonium salt having a C10 to C14 alkyl group, which is composed of cetylpyridinium chloride. The quaternary ammonium salt having a C10 to C14 alkyl group is
Equation (1):

(In the formula, R represents a C10 to C14 linear alkyl group, X represents Cl or Br), and the formula (2) :.

(In the formula, R ¹ represents a C10 to C14 linear alkyl group, R ² and R ³ represent the same or different C1 to C4 alkyl groups, and X represents Cl or Br). At least one selected from the group,
The plaque formation inhibitory effect enhancer according to claim 5. The quaternary ammonium salt having a C10 to C14 alkyl group is
Equation (1a):

Compounds represented by (in the formula, R is the same as above), and formula (2a) :.

(In the formula, R ¹ is at least one selected from the group consisting of the compounds represented by the above).
The plaque formation inhibitory effect enhancer according to claim 6. An agent for enhancing the bactericidal effect of a quaternary ammonium salt having a C10 to C14 alkyl group, which comprises cetylpyridinium chloride. The quaternary ammonium salt having a C10 to C14 alkyl group is
Equation (1):

(In the formula, R represents a C10 to C14 linear alkyl group, X represents Cl or Br), and the formula (2) :.

(In the formula, R ¹ represents a C10 to C14 linear alkyl group, R ² and R ³ represent the same or different C1 to C4 alkyl groups, and X represents Cl or Br). At least one selected from the group,
The Fusobacterium bactericidal effect enhancer according to claim 8. The quaternary ammonium salt having a C10 to C14 alkyl group is
Equation (1a):

Compounds represented by (in the formula, R is the same as above), and formula (2a) :.

(In the formula, R ¹ is at least one selected from the group consisting of the compounds represented by the above).
The fusobacterium bactericidal effect enhancer according to claim 9.

Images